Plummeting Prices of Generic Drugs Fueling US Medication Shortages

Over the past few years, the problem of drug shortages in the United States has moved from a marginal issue to an urgent public health challenge. According to authoritative research, 83% of drugs faced supply shortages in the most recent statistical cycle, which is a significant increase from the past. The net selling prices of these drugs generally declined between 2020 and 2022, reflecting the challenging conditions in the drug market. Prices of injectable and non-solid dosage forms fell particularly sharply, by an average of 23%, in large part because of the high production costs of these drugs, which are not covered by market prices.

The emergence of this phenomenon, in part, stems from the market's over-sensitivity to drug prices and continued low. Experts in the pharmaceutical industry point out that this market strategy of blindly pursuing low prices has had a serious impact on the production capacity of pharmaceutical companies. In order to maintain profits, companies may be forced to reduce production lines, lower production standards, or even withdraw from the production of certain drugs, resulting in a shortage of drugs. In addition, such price pressures may also inhibit pharmaceutical companies' investment in new drug research and development, further affecting drug innovation and supply.

In the face of this challenge, governments and healthcare organizations have come up with several strategies to deal with it. One widely discussed option is to implement a more flexible procurement strategy. This includes signing long-term minimum purchase volume contracts with drug manufacturers to guarantee a stable source of income for pharmaceutical companies to maintain or expand production. At the same time, such contracts also ensure that healthcare facilities have sufficient stocks of medicines to cope with possible supply disruptions.

However, solving the problem of drug shortages will not happen overnight, and it will require the joint efforts of policy makers, pharmaceutical companies, healthcare institutions, and the public. In addition to adjusting procurement strategies, a deep reform of drug pricing mechanisms is needed to ensure that prices reflect production costs and investment in research and development, while ensuring access and affordability of medicines. Only in this way can we fundamentally solve the deep-seated crisis of drug shortage and protect the drug demand and health rights and interests of the American public.